Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05975840 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 518
- Enrollment target
NCT05975840 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 518 participants.
The verdict
NCT05975840, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 518 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (\>=)18 years of age.
Interventions
- BIOLOGICAL FLU Q-PAN H5N8 375_B
- BIOLOGICAL FLU Q-PAN H5N8 375_A
- BIOLOGICAL FLU Q-PAN H5N8 750_B
- BIOLOGICAL FLU Q-PAN H5N8 750_A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2023-08-03 |
| Est. Completion | 2024-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05975840
The ClinicalTrials.gov registry entry for NCT05975840 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which FLU Q-PAN H5N8 375_B is the first listed.
NCT05975840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05975840 about?
NCT05975840 is a clinical study titled "Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults". The purpose of this study is to assess the safety and immunogenicity of different formulations of monovalent Influenza A/Astrakhan/3212/2020-like virus vaccine with AS03 adjuvant system in adults greater than or equal to (\>=)18 years of age.
What is the current status of trial NCT05975840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 518 participants. The study started on 2023-08-03. Estimated completion is 2024-09-19.
What interventions are being tested in trial NCT05975840?
The interventions under investigation include: FLU Q-PAN H5N8 375_B (BIOLOGICAL), FLU Q-PAN H5N8 375_A (BIOLOGICAL), FLU Q-PAN H5N8 750_B (BIOLOGICAL), FLU Q-PAN H5N8 750_A (BIOLOGICAL).
Who is sponsoring clinical trial NCT05975840?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.